```
=> b reg
FILE 'REGISTRY' ENTERED AT 11:45:11 ON 20 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 JUN 2006  HIGHEST RN 888406-82-4
DICTIONARY FILE UPDATES:  19 JUN 2006  HIGHEST RN 888406-82-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d que sta l25
L18                 STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  10

STEREO ATTRIBUTES: NONE
L20          409 SEA FILE=REGISTRY SSS FUL L18
L23              STR
```

noble jarrell 20/06/2006



VAR G1=AK/CY
VAR G2=H/AK/CY
VAR G3=H/X/N/AK/CB
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 1
CONNECT IS E2 RC AT 10
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L25 20 SEA FILE=REGISTRY SUB=L20 SSS FUL L23

100.0% PROCESSED 409 ITERATIONS 20 ANSWERS
SEARCH TIME: 00.00.03

=> d all fhitstr l28 tot
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:n

=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:45:31 ON 20 JUN 2006

FILE COVERS 1907 - 20 Jun 2006 VOL 144 ISS 26
FILE LAST UPDATED: 19 Jun 2006 (20060619/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d all fhitstr l28 tot

L28 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

noble jarrell 20/06/2006

AN 2004:267335 HCAPLUS
DN 140:287379
ED Entered STN: 01 Apr 2004
TI Preparation and pharmaceutical compositions of novel pyrazolopyridines as cyclin dependent kinase inhibitors
IN **Dwyer, Michael P.; Guzi, Timothy J.; Paruch, Kamil; Doll, Ronald J.; Keertikar, Kartik M.; Girijavallabhan, Viyyoor M.**
PA **Schering** Corporation, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D-0471/04
ICS A61K-0031/437; A61P-0035/00
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2004026872	A1	20040401	2003WO-US29841	20030917 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA---2499593	AA	20040401	2003CA-2499593	20030917 <--
AU2003270846	A1	20040408	2003AU-0270846	20030917 <--
US2004097516	A1	20040520	2003US-0664337	20030917 <--
EP---1539750	A1	20050615	2003EP-0752559	20030917 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN---1681816	A	20051012	2003CN-0822011	20030917 <--
JP2006503060	T2	20060126	2004JP-0538405	20030917 <--
ZA2005002271	A	20050919	2005ZA-0002271	20050317 <--
PRAI 2002US-412138P	P	20020919	<--	
2003WO-US29841	W	20030917		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004026872	ICM	C07D-0471/04
	ICS	A61K-0031/437; A61P-0035/00
	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-437 [ICS,7]; A61K0031-4353 [ICS,7,C*]; A61P0035-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	ECLA	C07D471/04+231C+221C
CA---2499593	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61P0035-00 [ICS,7]; A61K0031-437 [ICS,7]; A61K0031-4353 [ICS,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
AU2003270846	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-437 [ICS,7]; A61K0031-4353 [ICS,7,C*]; A61P0035-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
US2004097516	IPCI	A61K0031-496 [ICM,7]; A61K0031-4745 [ICS,7]; A61K0031-4738 [ICS,7,C*]; C07D0471-02 [ICS,7]; C07D0471-00 [ICS,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	NCL	514/253.040
	ECLA	C07D471/04+231C+221C
EP---1539750	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*];

noble jarrell 20/06/2006

		A61K0031-437 [ICS,7]; A61K0031-4353 [ICS,7,C*]; A61P0035-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
CN---1681816	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-437 [ICS,7]; A61K0031-4353 [ICS,7,C*]; A61P0035-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
JP2006503060	IPCI	C07D0471-04 [I,A]; C07D0471-00 [I,C*]; A61K0031-437 [I,A]; A61K0031-4353 [I,C*]; A61K0031-444 [I,A]; A61K0031-4427 [I,C*]; A61K0031-506 [I,A]; A61K0031-635 [I,A]; A61K0031-63 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,A]; A61P0035-02 [I,A]; A61P0043-00 [I,A]
	FTERM	4C065/AA03; 4C065/BB05; 4C065/CC01; 4C065/DD02; 4C065/EE02; 4C065/HH01; 4C065/HH02; 4C065/JJ07; 4C065/JJ08; 4C065/KK01; 4C065/LL01; 4C065/LL02; 4C065/PP03; 4C065/PP04; 4C065/PP10; 4C065/PP12; 4C065/PP13; 4C065/PP14; 4C084/AA19; 4C084/NA05; 4C084/ZB261; 4C084/ZB262; 4C084/ZB271; 4C084/ZB272; 4C084/ZC751; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/CB05; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZB26; 4C086/ZB27
ZA2005002271	IPCI	C07D [ICS,7]; A61K [ICS,7]; A61P [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	ECLA	C07D471/04+231C+221C

OS MARPAT 140:287379

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyridine compds. I [R = (un)substiuted-alkyl, -aryl, -heteroaryl, -heteroarylalkyl, etc.; R1 = H, alkyl or aryl; R2 = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -aryl, etc.; R3 = H, halo, CF3, (un)substituted-alkyl, -aryl, etc.; R4 = H, halo, CF3, (un)substituted-alkyl, -cycloalkyl, -aryl, -heteroaryl, etc.] as inhibitors of cyclin dependent kinases, methods of preparing such compds., pharmaceutical compns. containing one or more such compds., methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepared by condensation of 7-amino-5-phenylpyrazolo[1,5-a]pyridine (preparation given) with 3-formylpyridine. I possessed excellent CDK inhibitory properties as demonstrated by the IC50 value for III of 0.078 μM in inhibition of CDK2.

ST pyridine pyrazolo prepn cyclin dependent kinase inhibitor; pyrazolopyridine prepn CDK inhibitor pharmaceutical compn; pyrazole pyridino prepn CDK inhibitor

IT Lymphoma
(B-cell; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Lymphoma
(Burkitt's; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Sarcoma
(Kaposi's; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Lymphoma
(T-cell; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Epidermal growth factor receptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibodies to; claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyridines)

noble jarrell 20/06/2006

IT Neuroglia, neoplasm
(astrocytoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Uterus, neoplasm
(cervix; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Cytotoxic agents
(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyridines)
IT Radiotherapy
(claimed method for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyridines)
IT Intestine, neoplasm
(colon; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Mitogens
(cyclin dependent kinase; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Macrolides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epothilones; claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyridines)
IT Sarcoma
(fibrosarcoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Thyroid gland, neoplasm
(follicle cell; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Skin, neoplasm
(keratoacanthoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Astrocyte
(neoplasm, astrocytoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Schwann cell
(neoplasm, schwannoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Nerve, neoplasm
(neuroblastoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Lymphoma
(non-Hodgkin's; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Bone, neoplasm
Sarcoma
(osteosarcoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Acute lymphocytic leukemia
Acute myeloid leukemia
Acute promyelocytic leukemia
Antitumor agents
Bladder, neoplasm
Chronic myeloid leukemia
Drug delivery systems
Drug interactions
Esophagus, neoplasm
Gallbladder, neoplasm
Hairy cell leukemia
Hodgkin's disease
Human
Kidney, neoplasm
Leukemia
Liver, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Melanoma

noble jarrell 20/06/2006

Myelodysplastic syndromes
Neuroglia, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Skin, neoplasm
Stomach, neoplasm
Thyroid gland, neoplasm
(preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Cyclin dependent kinase inhibitors
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Carcinoma
(pulmonary small-cell; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Sarcoma
(rhabdomyosarcoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Nervous system, neoplasm
(schwannoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Testis, neoplasm
(seminoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Lung, neoplasm
(small-cell carcinoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Carcinoma
(squamous cell; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Carcinoma
(teratocarcinoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Skin, disease
(xeroderma pigmentosum; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT 50-07-7, Mitomycin-C 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-18-3, Triethylenemelamine 51-21-8, 5-Fluorouracil 51-75-2, Chlormethine 52-24-4, Triethylenethiophosphoramide 53-03-2, Prednisone 53-19-0, Mitotane 54-91-1, Pipobroman 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6, 17α-Ethinylestradiol 58-05-9, Leucovorin 58-18-4, Methyltestosterone 58-22-0, Testosterone 59-05-2, Methotrexate 66-75-1, Uracil mustard 68-96-2, Hydroxyprogesterone 71-58-9, Medroxyprogesterone acetate 76-43-7, Fluoxymesterone 83-43-2, Methylprednisolone 124-88-9, Intron 124-94-7, Triamcinolone 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 147-94-4, Ara-C 148-82-3, Melphalan 154-42-7, 6-Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil 521-12-0, Dromostanolone propionate 569-57-3, Chlorotrianisene 595-33-5, Megestrolacetate 645-05-6, Hexamethylmelamine 671-16-9, Procarbazine 865-21-4, Vinblastine 968-93-4, Testolactone 2998-57-4, Estramustine 3778-73-2, Ifosfamide 4342-03-4, Dacarbazine 9015-68-3, L-Asparaginase 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 14769-73-4, Levamisole 15663-27-1, Cisplatin 18378-89-7, Mithramycin 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 25316-40-9, Adriamycin 29767-20-2, Teniposide 33069-62-4, Taxol 33419-42-0, Etoposide 41575-94-4, Carboplatin 51264-14-3, Amsacrine 53643-48-4, Vindesine 53714-56-0, Leuprolide 53910-25-1, Pentostatin 56420-45-2, Epirubicin 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin 65271-80-9, Mitoxantrone 65807-02-5, Goserelin 75607-67-9, Fludarabine phosphate 85622-93-1, Temozolomide 89778-26-7, Toremifene 95058-81-4, Gemcitabine 97682-44-5, Irinotecan 100286-90-6, CPT-11 112809-51-5,

noble jarrell 20/06/2006

Letrozole 114977-28-5, Taxotere 120511-73-1, Anastrozole
123948-87-8, Topotecan 125317-39-7, Navelbine 154361-50-9,
Capecitabine 183319-69-9, Tarceva 184475-35-2, Iressa 192185-68-5, R
115777 193275-84-2, SCH 66336 195987-41-8, BMS 214662 220127-57-1,
Gleevec 253863-00-2, L778123
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin
dependent kinases in the presence of prepared pyrazolopyridines)

IT 9005-79-2, Glycogen, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cyclin dependent kinase; preparation of pyrazolopyridines as cyclin
dependent kinase inhibitors)

IT **676239-02-4P 676239-04-6P 676239-06-8P**
676239-09-1P 676239-12-6P 676239-16-0P
676239-19-3P 676239-21-7P 676239-22-8P
676239-24-0P 676239-26-2P 676239-28-4P
676239-30-8P 676239-32-0P 676239-34-2P 676239-37-5P
676239-41-1P 676239-44-4P 676239-46-6P 676239-48-8P
676239-50-2P 676239-51-3P 676239-52-4P 676239-55-7P
676239-58-0P 676239-63-7P 676270-66-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of pyrazolopyridines as cyclin dependent kinase
inhibitors)

IT 99446-34-1P 99446-40-9P 676239-66-0P 676239-69-3P 676239-71-7P
676239-74-0P 676239-76-2P 676239-79-5P 676239-82-0P 676239-84-2P
676239-86-4P 676239-87-5P 676239-89-7P 676239-91-1P 676239-93-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of pyrazolopyridines as cyclin dependent kinase
inhibitors)

IT 141349-86-2, Cyclin dependent kinase, CDK2 150428-23-2, Cyclin-dependent
kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT 121-61-9 500-22-1, 3-Formylpyridine 872-85-5, 4-Formylpyridine
939-23-1, 4-Phenylpyridine 1013-88-3, Benzophenone imine 3978-81-2,
4-(tert-Butyl)pyridine 5780-66-5, Pyrazinecarboxaldehyde 10400-19-8,
3-Pyridinecarboxylic acid chloride 14254-57-0, Pyridine-4-carboxylic
acid chloride 16133-25-8, 3-Pyridinesulfonylchloride 37477-17-1
676239-94-4 676239-96-6 676239-98-8 676240-01-0 676240-03-2
676240-06-5 676270-64-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of pyrazolopyridines as cyclin dependent
kinase inhibitors)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Gray, N; CURRENT MEDICINAL CHEMISTRY 1999, V6(9), P859 HCAPLUS
(2) Pet; WO---9716452 A 1997 HCAPLUS
(3) Senderowicz, A; JOURNAL OF THE NATIONAL CANCER INSTITUTE 2000, V92(5), P376
HCAPLUS
(4) Ulibarri, G; WO---0250079 A 2002 HCAPLUS

IT **676239-02-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of pyrazolopyridines as cyclin dependent kinase
inhibitors)

RN 676239-02-4 HCAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-phenyl-N-(3-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

noble jarrell 20/06/2006



=> d all hitstr l29 tot

L29 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:380361 HCAPLUS
DN 135:9814
ED Entered STN: 27 May 2001
TI Oxidative hair dye composition containing 3-amino pyrazolo-[1,5-a]-pyridines
IN Birault, Veronique; Leduc, Madeleine; Terranova, Eric
PA L'Oreal, Fr.
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA French
IC ICM A61K-0007/13
ICS C07D-0471/04; C07D-0471/04; C07D-0231/00; C07D-0221/00
CC 62-3 (Essential Oils and Cosmetics)
Section cross-reference(s): 28
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2001035917	A1	20010525	2000WO-FR02903	20001018
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR---2801308	A1	20010525	1999FR-0014582	19991119
	FR---2801308	B1	20030509		
	CA---2391980	AA	20010525	2000CA-2391980	20001018
	EP---1233743	A1	20020828	2000EP-0969640	20001018
	EP---1233743	B1	20060215		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP2004508275	T2	20040318	2001JP-0537710	20001018
	AT----317686	E	20060315	2000AT-0969640	20001018
	US---6730789	B1	20040504	2002US-0130535	20021217
	JP2005247856	A2	20050915	2005JP-0072091	20050314
PRAI	1999FR-0014582	A	19991119		
	2001JP-0537710	A3	20001018		
	2000WO-FR02903	W	20001018		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES

noble jarrell 20/06/2006



RN 340962-06-3 HCAPLUS
CN 1H-Imidazolium, 1-[2-[(3-aminopyrazolo[1,5-a]pyridin-7-yl)amino]-1-methylethyl]-3-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 340962-07-4 HCAPLUS
CN 1H-Imidazolium, 1-[2-[(3-aminopyrazolo[1,5-a]pyridin-7-yl)amino]-1-methylethyl]-3-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

WO 2001035917	ICM	A61K-0007/13
	ICS	C07D-0471/04; C07D-0471/04; C07D-0231/00; C07D-0221/00
	IPCI	A61K0007-13 [ICM,7]; C07D0471-04 [ICS,7]; C07D0471-00 [ICS,7,C*]; C07D0231-00 [ICS,7]; C07D0221-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	ECLA	A61Q005/10; A61K008/49F; C07D471/04+231C+221C
FR---2801308	IPCI	C07D0471-04 [ICM,7]; A61K0007-13 [ICS,7]; C07D0471-04 [ICI,7]; C07D0471-00 [ICI,7,C*]; C07D0213-89 [ICI,7]; C07D0213-00 [ICI,7,C*]; C07D0207-34 [ICI,7]; C07D0207-00 [ICI,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	ECLA	A61K007/13K4M; C07D471/04+231C+221C; A61Q005/10; A61K008/49F
CA---2391980	IPCI	A61K0007-13 [ICM,7]; C07D0221-00 [ICS,7]; C07D0231-00 [ICS,7]; C07D0471-04 [ICS,7]; C07D0471-00 [ICS,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	ECLA	A61Q005/10; A61K008/49F; C07D471/04+231C+221C
EP---1233743	IPCI	A61K0008-30 [I,C]; A61Q0005-10 [I,C]; A61K0008-49 [I,A]; A61Q0005-10 [I,A]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	ECLA	A61Q005/10; A61K008/49F; C07D471/04+231C+221C
JP2004508275	IPCI	A61K0007-13 [ICM,7]; C07D0471-04 [ICS,7]; C07D0471-00 [ICS,7,C*]; D06P0003-08 [ICS,7]; D06P0003-04 [ICS,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	FTERM	4C065/AA03; 4C065/BB05; 4C065/CC01; 4C065/DD02; 4C065/EE02; 4C065/HH01; 4C065/JJ07; 4C065/KK01; 4C065/LL07; 4C065/PP01; 4C083/AB082; 4C083/AB282; 4C083/AB331; 4C083/AB352; 4C083/AB411; 4C083/AB412; 4C083/AC102; 4C083/AC532; 4C083/AC552; 4C083/AC851; 4C083/AC852; 4C083/CC36; 4C083/DD23; 4C083/DD27; 4C083/EE03; 4C083/EE26; 4H057/AA02; 4H057/BA01; 4H057/BA09; 4H057/CA07; 4H057/CB45; 4H057/CB46; 4H057/CC02; 4H057/DA01; 4H057/DA21; 4H057/HA04; 4H057/HA05; 4H057/HA06
AT----317686	IPCI	A61K0008-49 [ICS,7]; A61K0008-30 [ICS,7,C*]; A61Q0005-10 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	ECLA	A61Q005/10; A61K008/49F; C07D471/04+231C+221C
US---6730789	IPCI	C07D0217-06 [ICM,7]; C07D0217-00 [ICM,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	NCL	546/121.000
	ECLA	A61Q005/10; A61K008/49F; C07D471/04+231C+221C
JP2005247856	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0007-13 [ICS,7]; D06P0003-08 [ICS,7]; D06P0003-04 [ICS,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	FTERM	4C065/AA03; 4C065/BB05; 4C065/CC01; 4C065/DD02; 4C065/EE02; 4C065/HH01; 4C065/JJ07; 4C065/KK01; 4C065/LL07; 4C065/PP09; 4C065/PP12; 4C083/AB082; 4C083/AB282; 4C083/AB352; 4C083/AB412; 4C083/AC102; 4C083/AC532; 4C083/AC552; 4C083/AC851; 4C083/AC852; 4C083/BB53; 4C083/CC36; 4C083/DD23; 4C083/DD27; 4C083/EE01; 4C083/EE07; 4C083/EE26; 4C083/FF01; 4H057/AA01; 4H057/AA02; 4H057/BA01; 4H057/BA09; 4H057/CA07; 4H057/CB45; 4H057/CB46; 4H057/CC02; 4H057/DA01; 4H057/DA21

OS MARPAT 135:9814

AB The invention concerns novel oxidative compns. for dyeing keratinous fibers comprising at least a 3-amino-pyrazolo-[1,5-a]-pyridine of derivs., the dyeing method using said composition, novel 3-amino pyrazolo-[1,5-a]-pyridines, and the method for preparing them. Thus, 3,4-diamino-pyrazolo-[1,4-a]-pyridine (I) was prepared by the reaction of 3,4-dinitro-pyrazolo-[1,4-a]-pyridine and hydrochloride acid. A hair dye preparation contained I 3.10-3 mole, 2,4-diamino-1-(β-hydroxyethyloxy)benzene 3.10-3, water and excipients q.s. 100 g. Equal amount of the composition is mixed with 20 volume hydrogen peroxide and applied on the hair to obtain a blond color.

noble jarrell 20/06/2006

ST oxidative hair dye aminopyrazolopyridine
IT Salts, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(of peroxy acids; oxidative hair dye composition containing aminopyrazolopyridines)
IT Oxidizing agents
(oxidative hair dye composition containing aminopyrazolopyridines)
IT Enzymes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oxidative hair dye composition containing aminopyrazolopyridines)
IT 89-25-8 90-15-3, 1-Naphthol 95-55-6D, o-Aminophenol, derivs. 95-88-5 106-50-3D, 1,4-Benzenediamine, derivs. 108-26-9 108-45-2, 1,3-Diaminobenzene, biological studies 108-46-3, 1,3-Dihydroxybenzene, biological studies 123-30-8D, p-Aminophenol, derivs. 124-43-6 533-31-3, Sesamol 591-27-5, 3-Aminophenol 608-25-3 2380-86-1, 6-Hydroxyindole 2380-94-1, 4-Hydroxyindole 2835-95-2, 2-Methyl-5-aminophenol 2933-77-9 4664-16-8, 2,6-Dihydroxy-4-methylpyridine 4770-37-0, 6-Hydroxyindoline 7469-77-4, 2-Methyl-1-naphthalenol 7556-37-8 7722-84-1, Hydrogen peroxide, biological studies 55302-96-0 70643-19-5 81892-72-0, 1,3-Bis-(2,4-diaminophenoxy)propane 136548-56-6 136548-62-4 137837-55-9, Pyrazolo[1,5-a]pyridin-3-amine 340961-82-2 340961-83-3 340961-84-4 340961-85-5 340961-86-6 340961-87-7 340961-88-8, Pyrazolo[1,5-a]pyridine-3,4-diamine 340961-89-9, Pyrazolo[1,5-a]pyridine-3,7-diamine 340961-90-2 340961-91-3, Pyrazolo[1,5-a]pyridine-3,5-diamine 340961-92-4 340961-93-5 340961-94-6 340961-95-7 340961-96-8 340961-97-9 340961-98-0 340961-99-1 340962-00-7 340962-01-8 340962-02-9 340962-03-0 340962-04-1 **340962-05-2** **340962-06-3** **340962-07-4** 340962-08-5 340962-09-6 340962-10-9
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oxidative hair dye composition containing aminopyrazolopyridines)
IT 136548-72-6P 136548-78-2P 340961-80-0P 340961-81-1P, Pyrazolo[1,5-a]pyridine-3,6-diamine
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oxidative hair dye composition containing aminopyrazolopyridines)
IT 274-56-6, Pyrazolo[1,5-a]pyridine 52199-03-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidative hair dye composition containing aminopyrazolopyridines)
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Boehringer Mannheim Gmbh; EP---0433855 A 1991 HCAPLUS
(2) Fadli, A; US---5980585 A 1999 HCAPLUS
(3) Frey, G; US---5234818 A 1993 HCAPLUS
(4) Fritz-Walter, L; US---3536436 A 1970
(5) Fujisawa Pharmaceutical Co; EP---0299209 A 1989 HCAPLUS
(6) Henkel Kgaa; EP---0030680 A 1981 HCAPLUS
(7) Oreal; EP---0904769 A 1999 HCAPLUS
(8) Oreal; FR---2771631 A 1999 HCAPLUS
IT **340962-05-2** **340962-06-3** **340962-07-4**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oxidative hair dye composition containing aminopyrazolopyridines)
RN 340962-05-2 HCAPLUS
CN Pyrazolo[1,5-a]pyridine-3,7-diamine, N7-[2-(1H-imidazol-1-yl)propyl]-(9CI) (CA INDEX NAME)

noble jarrell 20/06/2006



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

```
=>  b uspatall
FILE 'USPATFULL' ENTERED AT 11:45:59 ON 20 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:45:59 ON 20 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs fhitstr hitrn l31 1

L31  ANSWER 1 OF 2  USPATFULL on STN
AN     2004:127532  USPATFULL
TI     Novel pyrazolopyridines as cyclin dependent kinase inhibitors
IN     Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
       Guzi, Timothy J., Chatham, NJ, UNITED STATES
       Paruch, Kamil, Garwood, NJ, UNITED STATES
       Doll, Ronald J., Convent Station, NJ, UNITED STATES
       Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
       Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
PA     Schering Corporation (non-U.S. corporation)
PI     US2004097516       A1   20040520
AI     2003US-0664337     A1   20030917 (10)
PRAI   2002US-412138P      20020919 (60)
DT     Utility
FS     APPLICATION
LREP   SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000
       GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
CLMN   Number of Claims: 28
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 1735
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     In its many embodiments, the present invention provides a novel class of
       pyrazolo[1,5-a]pyridine compounds as inhibitors of cyclin dependent
       kinases, methods of preparing such compounds, pharmaceutical
       compositions containing one or more such compounds, methods of preparing
       pharmaceutical formulations comprising one or more such compounds, and
       methods of treatment, prevention, inhibition, or amelioration of one or
       more diseases associated with the CDKs using such compounds or
       pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT  676239-02-4P
```

noble jarrell 20/06/2006

(drug candidate; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
RN 676239-02-4 USPATFULL
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-phenyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



IT 676239-02-4P 676239-04-6P 676239-06-8P
676239-09-1P 676239-12-6P 676239-16-0P
676239-19-3P 676239-21-7P 676239-22-8P
676239-24-0P 676239-26-2P 676239-28-4P
676239-30-8P 676239-50-2P 676239-58-0P
676239-63-7P 676270-66-9P
(drug candidate; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

=> d bib abs hitstr l31 2

L31 ANSWER 2 OF 2 USPATFULL on STN
AN 2004:109984 USPATFULL
TI Composition for dyeing keratinous fibers containing 3 amino pyrazolo-[1,5-a] pyridines, dyeing method, novel 3-amino pyrazolo-[1,5-a] pyridines
IN Birault, Veronique, Saffron Walden, UNITED KINGDOM
Leduc, Madeleine, Paris, FRANCE
Terranova, Eric, Magagnosc, FRANCE
PA L'Oreal S.A., Paris, FRANCE (non-U.S. corporation)
PI US---6730789 B1 20040504
WO2001035917 20010525
AI 2002US-0130535 20021217 (10)
2000WO-FR02903 20001018
PRAI 1999FR-0014582 19991119
DT Utility
FS GRANTED
EXNAM Primary Examiner: Seaman, D. Margaret
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ##STR1## The invention concerns novel oxidative composition for dyeing keratinous fibres comprising at least a 3-amino-pyrazolo-[1,5-a]-pyridine of Formula (I), the dyeing method using said composition, novel 3-amino pyrazolo-[1,5-a]-pyridines, and the method for preparing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 340962-05-2 340962-06-3 340962-07-4
(oxidative hair dye composition containing aminopyrazolopyridines)

noble jarrell 20/06/2006

RN 340962-05-2 USPATFULL
CN Pyrazolo[1,5-a]pyridine-3,7-diamine, N7-[2-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 340962-06-3 USPATFULL
CN 1H-Imidazolium, 1-[2-[(3-aminopyrazolo[1,5-a]pyridin-7-yl)amino]-1-methylethyl]-3-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 340962-07-4 USPATFULL
CN 1H-Imidazolium, 1-[2-[(3-aminopyrazolo[1,5-a]pyridin-7-yl)amino]-1-methylethyl]-3-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

```
=> d his

     (FILE 'HOME' ENTERED AT 11:15:17 ON 20 JUN 2006)

     FILE 'HCAPLUS' ENTERED AT 11:15:29 ON 20 JUN 2006
L1             1 US2004097516/PN OR (US2003-664337 OR US2002-412138#)/AP,PRN
                 E SWYER M/AU
                 E DWYER M/AU
L2            13 E3
                 E DWYER MI/AU
L3            41 E4,E7-8
                 E GUZI T/AU
L4            48 E3-6
                 E PARUCH K/AU
L5            32 E4-5
                 E DOLL R/AU
L6            50 E3,E6
L7           129 E14-16
                 E KEERTIKAR K/AU
L8            19 E3-5
                 E GIRIJAVALLABHAN V/AU
L9           262 E3-4,E8-16
L10        14362 SCHERING/CS,PA

     FILE 'REGISTRY' ENTERED AT 11:21:21 ON 20 JUN 2006

     FILE 'HCAPLUS' ENTERED AT 11:21:21 ON 20 JUN 2006
L11              TRA L1 1- RN :      152 TERMS

     FILE 'REGISTRY' ENTERED AT 11:21:21 ON 20 JUN 2006
L12          152 SEA L11
L13           49 L12 AND N2C3-NC5/ES
L14              STR
                 SAV TEM L22 WARD337F0/A
L15              STR L14
L16            0 L15
L17              STR L15
L18              STR L17
L19           27 L18
L20          409 L18 FULL
                 SAV TEM WARD337F0/A L20
L21              STR L15
```

noble jarrell 20/06/2006

```
L22           19 L21 SAM SUB=L20
L23              STR L21
L24            2 L23 SAM SUB=L20
L25           20 L23 FULL SUB=L20
L26           43 L12 AND L20,L25

     FILE 'HCAPLUS' ENTERED AT 11:42:49 ON 20 JUN 2006
L27            2 L25
L28            1 L27 AND L1-10
L29            1 L27 NOT L28

     FILE 'HCAOLD' ENTERED AT 11:44:30 ON 20 JUN 2006
L30            0 L25

     FILE 'USPATFULL, USPAT2' ENTERED AT 11:44:39 ON 20 JUN 2006
L31            2 L25

=>
```

noble jarrell 20/06/2006

```
=> b reg;d ide can l34 tot
FILE 'REGISTRY' ENTERED AT 11:50:43 ON 20 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 JUN 2006  HIGHEST RN 888406-82-4
DICTIONARY FILE UPDATES:  19 JUN 2006  HIGHEST RN 888406-82-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html


L34  ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   676239-06-8  REGISTRY
ED   Entered STN:  20 Apr 2004
CN   Pyrazolo[1,5-a]pyridin-7-amine, 3-bromo-5-phenyl-N-(4-pyridinylmethyl)-
     (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C19 H15 Br N4
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
```



noble jarrell 20/06/2006

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:287379

L34 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
RN **676239-04-6** REGISTRY
ED Entered STN: 20 Apr 2004
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-bromo-5-phenyl-N-(3-pyridinylmethyl)-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C19 H15 Br N4**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:287379

=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:51:10 ON 20 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Jun 2006 VOL 144 ISS 26
FILE LAST UPDATED: 19 Jun 2006 (20060619/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

noble jarrell 20/06/2006

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr l36 tot

L36 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:267335 HCAPLUS
DN 140:287379
ED Entered STN: 01 Apr 2004
TI Preparation and pharmaceutical compositions of novel pyrazolopyridines as cyclin dependent kinase inhibitors
IN **Dwyer, Michael P.; Guzi, Timothy J.; Paruch, Kamil; Doll, Ronald J.; Keertikar, Kartik M.; Girijavallabhan, Viyyoor M.**
PA **Schering** Corporation, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D-0471/04
ICS A61K-0031/437; A61P-0035/00
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2004026872	A1	20040401	2003WO-US29841	20030917 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA---2499593	AA	20040401	2003CA-2499593	20030917 <--
AU2003270846	A1	20040408	2003AU-0270846	20030917 <--
US2004097516	A1	20040520	2003US-0664337	20030917 <--
EP---1539750	A1	20050615	2003EP-0752559	20030917 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN---1681816	A	20051012	2003CN-0822011	20030917 <--
JP2006503060	T2	20060126	2004JP-0538405	20030917 <--
ZA2005002271	A	20050919	2005ZA-0002271	20050317 <--
PRAI 2002US-412138P	P	20020919 <--		
2003WO-US29841	W	20030917		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004026872	ICM	C07D-0471/04
	ICS	A61K-0031/437; A61P-0035/00
	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-437 [ICS,7]; A61K0031-4353 [ICS,7,C*]; A61P0035-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	ECLA	C07D471/04+231C+221C
CA---2499593	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61P0035-00 [ICS,7]; A61K0031-437 [ICS,7]; A61K0031-4353 [ICS,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
AU2003270846	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-437 [ICS,7]; A61K0031-4353 [ICS,7,C*]; A61P0035-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]

noble jarrell 20/06/2006

US2004097516	IPCI	A61K0031-496 [ICM,7]; A61K0031-4745 [ICS,7]; A61K0031-4738 [ICS,7,C*]; C07D0471-02 [ICS,7]; C07D0471-00 [ICS,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	NCL	514/253.040
	ECLA	C07D471/04+231C+221C
EP---1539750	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-437 [ICS,7]; A61K0031-4353 [ICS,7,C*]; A61P0035-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
CN---1681816	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-437 [ICS,7]; A61K0031-4353 [ICS,7,C*]; A61P0035-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
JP2006503060	IPCI	C07D0471-04 [I,A]; C07D0471-00 [I,C*]; A61K0031-437 [I,A]; A61K0031-4353 [I,C*]; A61K0031-444 [I,A]; A61K0031-4427 [I,C*]; A61K0031-506 [I,A]; A61K0031-635 [I,A]; A61K0031-63 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,A]; A61P0035-02 [I,A]; A61P0043-00 [I,A]
	FTERM	4C065/AA03; 4C065/BB05; 4C065/CC01; 4C065/DD02; 4C065/EE02; 4C065/HH01; 4C065/HH02; 4C065/JJ07; 4C065/JJ08; 4C065/KK01; 4C065/LL01; 4C065/LL02; 4C065/PP03; 4C065/PP04; 4C065/PP10; 4C065/PP12; 4C065/PP13; 4C065/PP14; 4C084/AA19; 4C084/NA05; 4C084/ZB261; 4C084/ZB262; 4C084/ZB271; 4C084/ZB272; 4C084/ZC751; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/CB05; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZB26; 4C086/ZB27
ZA2005002271	IPCI	C07D [ICS,7]; A61K [ICS,7]; A61P [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-04 [I,A]
	ECLA	C07D471/04+231C+221C

OS MARPAT 140:287379
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyridine compds. I [R = (un)substiuted-alkyl, -aryl, -heteroaryl, -heteroarylalkyl, etc.; R1 = H, alkyl or aryl; R2 = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -aryl, etc.; R3 = H, halo, CF3, (un)substituted-alkyl, -aryl, etc.; R4 = H, halo, CF3, (un)substituted-alkyl, -cycloalkyl, -aryl, -heteroaryl, etc.] as inhibitors of cyclin dependent kinases, methods of preparing such compds., pharmaceutical compns. containing one or more such compds., methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepared by condensation of 7-amino-5-phenylpyrazolo[1,5-a]pyridine (preparation given) with 3-formylpyridine. I possessed excellent CDK inhibitory properties as demonstrated by the IC50 value for III of 0.078 μM in inhibition of CDK2.

ST pyridine pyrazolo prepn cyclin dependent kinase inhibitor; pyrazolopyridine prepn CDK inhibitor pharmaceutical compn; pyrazole pyridino prepn CDK inhibitor

IT Lymphoma
(B-cell; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Lymphoma
(Burkitt's; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Sarcoma
(Kaposi's; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

noble jarrell 20/06/2006

IT Lymphoma
(T-cell; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Epidermal growth factor receptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibodies to; claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyridines)
IT Neuroglia, neoplasm
(astrocytoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Uterus, neoplasm
(cervix; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Cytotoxic agents
(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyridines)
IT Radiotherapy
(claimed method for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyridines)
IT Intestine, neoplasm
(colon; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Mitogens
(cyclin dependent kinase; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Macrolides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epothilones; claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyridines)
IT Sarcoma
(fibrosarcoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Thyroid gland, neoplasm
(follicle cell; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Skin, neoplasm
(keratoacanthoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Astrocyte
(neoplasm, astrocytoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Schwann cell
(neoplasm, schwannoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Nerve, neoplasm
(neuroblastoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Lymphoma
(non-Hodgkin's; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Bone, neoplasm
Sarcoma
(osteosarcoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
IT Acute lymphocytic leukemia
Acute myeloid leukemia
Acute promyelocytic leukemia
Antitumor agents
Bladder, neoplasm
Chronic myeloid leukemia
Drug delivery systems
Drug interactions
Esophagus, neoplasm
Gallbladder, neoplasm
Hairy cell leukemia
Hodgkin's disease

noble jarrell 20/06/2006

Human
Kidney, neoplasm
Leukemia
Liver, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Melanoma
Myelodysplastic syndromes
Neuroglia, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Skin, neoplasm
Stomach, neoplasm
Thyroid gland, neoplasm
(preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Cyclin dependent kinase inhibitors
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Carcinoma
(pulmonary small-cell; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Sarcoma
(rhabdomyosarcoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Nervous system, neoplasm
(schwannoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Testis, neoplasm
(seminoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Lung, neoplasm
(small-cell carcinoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Carcinoma
(squamous cell; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Carcinoma
(teratocarcinoma; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT Skin, disease
(xeroderma pigmentosum; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT 50-07-7, Mitomycin-C 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-18-3, Triethylenemelamine 51-21-8, 5-Fluorouracil 51-75-2, Chlormethine 52-24-4, Triethylenethiophosphoramide 53-03-2, Prednisone 53-19-0, Mitotane 54-91-1, Pipobroman 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6, 17α-Ethinylestradiol 58-05-9, Leucovorin 58-18-4, Methyltestosterone 58-22-0, Testosterone 59-05-2, Methotrexate 66-75-1, Uracil mustard 68-96-2, Hydroxyprogesterone 71-58-9, Medroxyprogesterone acetate 76-43-7, Fluoxymesterone 83-43-2, Methylprednisolone 124-88-9, Intron 124-94-7, Triamcinolone 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 147-94-4, Ara-C 148-82-3, Melphalan 154-42-7, 6-Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil 521-12-0, Dromostanolone propionate 569-57-3, Chlorotrianisene 595-33-5, Megestrolacetate 645-05-6, Hexamethylmelamine 671-16-9, Procarbazine 865-21-4, Vinblastine 968-93-4, Testolactone 2998-57-4, Estramustine 3778-73-2, Ifosfamide 4342-03-4, Dacarbazine 9015-68-3, L-Asparaginase 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 14769-73-4, Levamisole 15663-27-1, Cisplatin 18378-89-7, Mithramycin 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 25316-40-9, Adriamycin

noble jarrell 20/06/2006

29767-20-2, Teniposide 33069-62-4, Taxol 33419-42-0, Etoposide
41575-94-4, Carboplatin 51264-14-3, Amsacrine 53643-48-4, Vindesine
53714-56-0, Leuprolide 53910-25-1, Pentostatin 56420-45-2, Epirubicin
58957-92-9, Idarubicin 61825-94-3, Oxaliplatin 65271-80-9,
Mitoxantrone 65807-02-5, Goserelin 75607-67-9, Fludarabine phosphate
85622-93-1, Temozolomide 89778-26-7, Toremifene 95058-81-4,
Gemcitabine 97682-44-5, Irinotecan 100286-90-6, CPT-11 112809-51-5,
Letrozole 114977-28-5, Taxotere 120511-73-1, Anastrozole
123948-87-8, Topotecan 125317-39-7, Navelbine 154361-50-9,
Capecitabine 183319-69-9, Tarceva 184475-35-2, Iressa 192185-68-5, R
115777 193275-84-2, SCH 66336 195987-41-8, BMS 214662 220127-57-1,
Gleevec 253863-00-2, L778123
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyridines)

IT 9005-79-2, Glycogen, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cyclin dependent kinase; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT **676239-02-4P 676239-04-6P 676239-06-8P** 676239-09-1P
676239-12-6P 676239-16-0P 676239-19-3P 676239-21-7P 676239-22-8P
676239-24-0P 676239-26-2P 676239-28-4P 676239-30-8P 676239-32-0P
676239-34-2P 676239-37-5P 676239-41-1P 676239-44-4P 676239-46-6P
676239-48-8P 676239-50-2P 676239-51-3P 676239-52-4P 676239-55-7P
676239-58-0P 676239-63-7P 676270-66-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT 99446-34-1P 99446-40-9P 676239-66-0P 676239-69-3P 676239-71-7P
676239-74-0P 676239-76-2P 676239-79-5P 676239-82-0P 676239-84-2P
676239-86-4P 676239-87-5P 676239-89-7P 676239-91-1P 676239-93-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT 141349-86-2, Cyclin dependent kinase, CDK2 150428-23-2, Cyclin-dependent kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

IT 121-61-9 500-22-1, 3-Formylpyridine 872-85-5, 4-Formylpyridine
939-23-1, 4-Phenylpyridine 1013-88-3, Benzophenone imine 3978-81-2,
4-(tert-Butyl)pyridine 5780-66-5, Pyrazinecarboxaldehyde 10400-19-8,
3-Pyridinecarboxylic acid chloride 14254-57-0, Pyridine-4-carboxylic acid chloride 16133-25-8, 3-Pyridinesulfonylchloride 37477-17-1
676239-94-4 676239-96-6 676239-98-8 676240-01-0 676240-03-2
676240-06-5 676270-64-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Gray, N; CURRENT MEDICINAL CHEMISTRY 1999, V6(9), P859 HCAPLUS
(2) Pet; WO---9716452 A 1997 HCAPLUS
(3) Senderowicz, A; JOURNAL OF THE NATIONAL CANCER INSTITUTE 2000, V92(5), P376 HCAPLUS
(4) Ulibarri, G; WO---0250079 A 2002 HCAPLUS

IT **676239-04-6P 676239-06-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)

RN 676239-04-6 HCAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-bromo-5-phenyl-N-(3-pyridinylmethyl)-

noble jarrell 20/06/2006

(9CI) (CA INDEX NAME)



RN 676239-06-8 HCAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-bromo-5-phenyl-N-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



=> b uspatall
FILE 'USPATFULL' ENTERED AT 11:54:02 ON 20 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:54:02 ON 20 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l38

L38 ANSWER 1 OF 1 USPATFULL on STN
AN 2004:127532 USPATFULL
TI Novel pyrazolopyridines as cyclin dependent kinase inhibitors
IN Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
PA Schering Corporation (non-U.S. corporation)
PI US2004097516 A1 20040520
AI 2003US-0664337 A1 20030917 (10)
PRAI 2002US-412138P 20020919 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000
GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530

noble jarrell 20/06/2006

CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1735
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyridine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **676239-04-6P 676239-06-8P**
(drug candidate; preparation of pyrazolopyridines as cyclin dependent kinase inhibitors)
RN 676239-04-6 USPATFULL
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-bromo-5-phenyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 676239-06-8 USPATFULL
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-bromo-5-phenyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



=> d his l32-

FILE 'REGISTRY' ENTERED AT 11:48:40 ON 20 JUN 2006
L32 9 L25 AND NC5/ES AND BR/ELS
L33 4 L32 AND 46.150.18/RID

noble jarrell 20/06/2006

```
                SEL RN 3-4
L34             2 E1-2 AND L33

     FILE 'HCAPLUS' ENTERED AT 11:50:18 ON 20 JUN 2006
L35             1 L34
L36             1 L35 AND L1-10

     FILE 'HCAOLD' ENTERED AT 11:53:30 ON 20 JUN 2006
L37             0 L34

     FILE 'USPATFULL, USPAT2' ENTERED AT 11:53:40 ON 20 JUN 2006
L38             1 L34
```

noble jarrell 20/06/2006